DEA Telemedicine Prescribing Rules Run Through 2026

Practitioners can keep prescribing controlled substances after a real-time audio-video telemedicine visit — without a prior in-person visit — through December 31, 2026. That's the effect of the temporary rule DEA and HHS issued in the final days of December 2025 — the fourth extension of the prescribing flexibilities that began during the public health emergency.

The rule keeps the framework simple on its face: DEA-registered practitioners may prescribe Schedule II–V controlled substances after a real-time audio-video telemedicine encounter, regardless of when the practitioner-patient relationship was formed. Audio-only encounters qualify only for Schedule III–V narcotic medications approved by the FDA to treat opioid use disorder, such as buprenorphine. Every prescription must still meet the rule's other conditions (90 FR 61301). State law still applies on top — and that's where much of the real complexity lives, since states layer their own prescription monitoring checks, e-prescribing mandates, and schedule-specific limits over the federal floor. Our state law guide tracks those differences.

Why a fourth extension is the story

This is the fourth time DEA has extended the flexibilities rather than landing a permanent rule. The agency proposed a special registration framework in early 2025 — a pathway that would let qualifying practitioners prescribe via telemedicine under a dedicated registration — but it has not been finalized. Every extension buys another year of access for patients, and another year of uncertainty for anyone building a prescribing-dependent program.

The stakes are concentrated in a few areas of medicine. Telepsychiatry practices prescribing stimulants for ADHD or benzodiazepines depend on this framework more than almost anyone else. Opioid use disorder programs have a narrower permanent fallback: since December 31, 2025, 21 CFR 1306.51 has allowed buprenorphine and other FDA-approved Schedule III–V opioid use disorder medications to be prescribed by telemedicine, including audio-only, for up to six calendar months from the first prescription, once the prescriber has reviewed the patient's state prescription drug monitoring program data. After that, an in-person medical evaluation or another pathway allowed under federal law is needed. If your program's economics assume telemedicine prescribing continues past 2026, that assumption deserves a contingency plan — most practically, a referral relationship or hybrid model that can absorb an in-person evaluation requirement if one returns. Our telepsychiatry guide covers how programs handle the controlled-substance question in practice.

What to watch between now and January 2027

Three things will tell you where this lands: whether DEA finalizes the special registration rule, whether Congress steps in legislatively, and whether a fifth temporary extension arrives late in the year, as the fourth did on December 31, 2025. We'll cover each development as it happens. Until then, treat December 31, 2026 as a real date: verify current requirements with DEA and your state board before writing prescribing policy around any of it.